Cargando…
Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case–control study
OBJECTIVE: The SAVOR TIMI–53 study reported a significant increase in the risk of hospitalisation for heart failure (HF) in patients treated with a DPP-4 inhibitor (DPP-4i) in comparison with placebo. A recent case-control study in part confirmed this risk signal. Our aim was to compare the occurren...
Autores principales: | Giorda, Carlo B, Picariello, Roberta, Tartaglino, Barbara, Marafetti, Lisa, Di Noi, Fabiana, Alessiato, Annalisa, Costa, Giuseppe, Gnavi, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458680/ https://www.ncbi.nlm.nih.gov/pubmed/26048211 http://dx.doi.org/10.1136/bmjopen-2015-007959 |
Ejemplares similares
-
The Impact of Adherence to Screening Guidelines and of Diabetes Clinics Referral on Morbidity and Mortality in Diabetes
por: Giorda, Carlo, et al.
Publicado: (2012) -
Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013) -
A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023) -
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020) -
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022)